The U.S. has the best medical care in the world, so people shouldn't panic over the first Ebola diagnosis in the country, an Ebola survivor said.» Read More
Pfizer reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
Nnew research suggests that, even without a match, some popular e-cigarettes get so hot that they, too, can produce a handful of the carcinogens found in cigarettes and at similar levels. The NYT reports.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
The number of nonpaying Obamacare enrollees is going to be huge, says Jake Novak.
Some states whose governors were hostile toward Obamacare exceeded enrollment projections, while some big boosters fell short.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
HHS Secretary Kathleen Sebelius says the enrollment tally exceeded expectations, and "demonstrated brisk demand for quality, affordable coverage."
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
A report released Wednesday said one-third of people who signed up for health insurance through new federal exchanges hadn't paid their first month's premium.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Danish insulin manufacturer has posted 15 percent growth in first-quarter operating profit but cut its sales outlook for 2014.
Four companies that charged New Yorkers as much as 55 percent interest for medical loans will pay 317 borrowers about $230,000 to settle usury claims.
Two proposals in Congress are taking aim at deadly superbugs. But it's not exactly clear to some experts just what the right medicine should be.
A majority of the nation's states either declined or failed to improve in nearly two dozen health indicators from 2007 to 2012, a new report said.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
WellPoint reported profit that beat analysts' expectations and said individual exchanges were operating at a profit.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
A new NBC News/Wall Street Journal poll shows that 44 percent of Americans now approve of Obama's job performance as Obamacare enrollment grows.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.
Get the best of CNBC in your inbox